Real-world data show erenumab and galcanezumab effectively reduce migraine frequency in patients unresponsive to onabotulinumtoxinA, indicating their importance in treatment.
In patients with chronic migraine refractory to OnabotulinumtoxinA, erenumab and galcanezumab produced comparable and sustained reductions in migraine frequency, with high responder rates. Treatment was associated with reduced triptan use, supporting the clinical relevance of anti-CGRP monoclonal antibodies in this population.
No takes yet. Share an insight, caveat, or question.
Martín-Yeves et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: